Pneumonia — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive coding, clinical, and documentation guidance for pneumonia across all organism types and care settings. Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 – September 30, 2026) and incorporates the most current clinical, reimbursement, and HCC risk-adjustment resources. Use this guide to ensure accurate diagnosis code assignment, appropriate organism-level specificity, CDI query triggers, and defensible documentation for pneumonia encounters across inpatient and outpatient settings.

🔍 1. Definition

Pneumonia is an acute infection of the lung parenchyma — the alveoli and surrounding interstitium — causing inflammation and fluid or purulent exudate that impairs gas exchange. According to the National Heart, Lung, and Blood Institute (NHLBI), pneumonia can be caused by bacteria, viruses, fungi, or other organisms, and severity ranges from mild outpatient illness to life-threatening respiratory failure requiring mechanical ventilation.

From an ICD-10-CM coding perspective, pneumonia is not a single condition but rather a category of infections classified by organism specificity (the primary coding determinant), site within the lung, care setting of acquisition (community-acquired vs. hospital-acquired vs. ventilator-associated), and aspiration mechanism. The FY2026 ICD-10-CM Tabular List classifies most pneumonias within Chapter 10 (Diseases of the Respiratory System, J00–J99), with additional codes in Chapter 1 (Infectious/Parasitic Diseases) when the causative organism is separately indexed.

Epidemiology: Pneumonia is one of the leading causes of hospitalization in the United States. The CDC reports that approximately 1.5 million Americans are hospitalized for pneumonia annually, with over 40,000 deaths per year. Community-acquired pneumonia (CAP) accounts for the majority of episodes; hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) carry substantially higher mortality and resource utilization.

Pneumonia by Acquisition Setting

• Community-Acquired Pneumonia (CAP): Develops outside the hospital or within 48 hours of admission in a patient not previously hospitalized; most common organisms are Streptococcus pneumoniae, Mycoplasma pneumoniae, respiratory viruses, and Legionella.
• Hospital-Acquired Pneumonia (HAP): Develops ≥48 hours after hospital admission, not incubating at admission; gram-negative bacilli and Staphylococcus aureus predominate per IDSA guidelines.
• Ventilator-Associated Pneumonia (VAP): A subset of HAP occurring in mechanically ventilated patients; coded J95.851 per FY2026 ICD-10-CM.
• Aspiration Pneumonia: Results from inhalation of oropharyngeal or gastric contents; coded J69.0 and carries HCC 280 (~0.329 RAF) under CMS-HCC Model v28.

🗂️ 2. Alternative Terminology

Coders and CDI specialists will encounter many terms in provider documentation that map to specific pneumonia codes. Understanding equivalent terminology is critical for accurate code assignment.

🩺 3. Signs & Symptoms

Clinical presentation guides both diagnosis and documentation specificity. CDI specialists should review the chart for these findings to support organism-level query triggers per ACDIS CDI practice standards:

Classic Symptoms

• Productive cough (purulent sputum in bacterial; scant in atypical/viral)
• Fever (temperature >38.0°C / 100.4°F) with or without chills/rigors
• Dyspnea and increased respiratory rate (tachypnea)
• Pleuritic chest pain (sharp, worse with inspiration — suggests lobar involvement)
• Hypoxemia (SpO₂ <94% or PaO₂/FiO₂ ratio <300 in severe cases)
• Malaise, fatigue, anorexia
• Altered mental status (especially in elderly — an underrecognized presentation)

Physical Examination Findings

• Tachycardia, tachypnea, hypotension (in sepsis/severe cases)
• Bronchial breath sounds, dullness to percussion over consolidation
• Egophony (“E to A” change), whispered pectoriloquy
• Crackles/rales on auscultation
• Decreased breath sounds (pleural effusion)

Diagnostic Findings Driving Code Specificity

• Chest X-ray / CT scan: Lobar consolidation, interstitial infiltrates, ground-glass opacities
• Gram stain and culture: Most important for organism specificity; coders should query when gram stain documents organism class but attending diagnosis is “pneumonia, unspecified”
• Blood cultures: Positive cultures shift coding to bacteremic pneumonia ± sepsis (A40.x/A41.x)
• Sputum culture: Organism-level identification enables J13–J16 vs. J18.9
• Urinary antigen tests: Streptococcus pneumoniae and Legionella antigens
• Respiratory PCR panels: Influenza A/B, RSV, SARS-CoV-2, hMPV, parainfluenza
• Procalcitonin / WBC: Supports bacterial vs. viral distinction for CDI query
• Bronchoscopy/BAL cultures: Key for VAP and immunocompromised patients

🧭 4. Differential Diagnosis

Accurate coding requires distinguishing pneumonia from conditions that may mimic it radiographically or clinically. The following differential diagnoses are relevant for coders and CDI specialists when validating provider documentation:

📋 5. Clinical Indicators for Coders/CDI

The following table maps documentation elements to their coding impact, supporting accurate code assignment and meaningful CDI queries per AHIMA coding standards:

🦴 6. Anatomy & Pathophysiology

Understanding the pathophysiology of pneumonia is essential for coding accuracy and query formulation. The lower respiratory tract — below the vocal cords — includes the trachea, bronchi, bronchioles, alveolar ducts, and alveoli. Pneumonia specifically involves the alveolar and interstitial compartments, as described by NHLBI.

Pathophysiologic Mechanisms by Organism Class

• Bacterial pneumonia: Organisms (e.g., S. pneumoniae, Klebsiella) colonize the lower airways and trigger an intense neutrophilic inflammatory response. Alveolar exudate (lobar consolidation) impairs gas exchange. Bacteremia and sepsis can ensue when organisms breach the alveolar-capillary barrier.
• Atypical bacterial pneumonia: Organisms such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila cause predominantly interstitial inflammation with less alveolar exudate — hence the “atypical” presentation with scant productive cough and often normal initial CXR.
• Viral pneumonia: Viruses (influenza, RSV, SARS-CoV-2) infect type I and II pneumocytes directly, triggering cytokine-mediated inflammatory cascades. COVID-19 pneumonia (U07.1 + J12.82) may progress to diffuse alveolar damage (DAD) and ARDS.
• Fungal pneumonia: Occurs primarily in immunocompromised hosts. Pneumocystis jirovecii (B59) attaches to type I pneumocytes causing alveolar flooding; Aspergillus (B44) invades vascular structures causing hemorrhagic infarction.
• Aspiration pneumonia: Aspiration of oropharyngeal bacteria-laden secretions or gastric contents triggers an anaerobic bacterial infection (J69.0) or, with sterile gastric acid, a chemical pneumonitis (J68.0). Risk factors include dysphagia, altered mental status, seizures, and nasogastric tube use.

HAP/VAP Pathophysiology

Hospital-acquired organisms colonize the oropharynx and, through microaspiration, reach the lower airways. In mechanically ventilated patients, the endotracheal tube bypasses natural airway defenses; VAP (J95.851) develops when these hospital-acquired organisms (commonly Pseudomonas aeruginosa, Acinetobacter, MRSA) establish infection per IDSA HAP/VAP guidelines.

💊 7. Medication Impact / Treatment

Medication documentation is a critical component of clinical validation for pneumonia coding. Treatment regimen supports — and sometimes establishes — organism type for CDI query purposes. According to IDSA CAP guidelines (2019, updated 2024):

Antibiotic Treatment by Organism / Setting

• CAP (outpatient, mild): Amoxicillin or doxycycline for typical organisms; azithromycin/doxycycline for atypical
• CAP (inpatient, non-ICU): Beta-lactam + macrolide (e.g., ceftriaxone + azithromycin) or respiratory fluoroquinolone (levofloxacin, moxifloxacin); HCPCS J0696 (ceftriaxone), J0744 (ciprofloxacin)
• CAP (ICU/severe): Beta-lactam + macrolide or fluoroquinolone; add anti-MRSA coverage (vancomycin, linezolid) if risk factors present
• HAP/VAP: Broad-spectrum anti-pseudomonal coverage — piperacillin-tazobactam (J2543), cefepime, meropenem ± vancomycin/linezolid per IDSA HAP/VAP guidelines; ceftolozane-tazobactam (J0695) for MDR Pseudomonas
• Aspiration pneumonia: Anaerobic coverage (ampicillin-sulbactam, clindamycin, metronidazole); aspirated sterile acid (pneumonitis) may not require antibiotics initially
• MRSA pneumonia: Vancomycin or linezolid; treatment of MRSA supports J15.212 query
• Fungal pneumonia (PCP): TMP-SMX (Bactrim) — first-line for Pneumocystis jirovecii (B59); pentamidine IV (J2545) for sulfa allergy
• Viral (influenza): Oseltamivir (Tamiflu — PO, J3535 not applicable for IV; note J3535 is oral agent, separate billing); J10.00/J10.01/J09.X1 depending on confirmed type
• COVID-19 pneumonia: Remdesivir, dexamethasone, supplemental oxygen; U07.1 + J12.82 coding; severity drives DRG assignment

Supportive and Respiratory Treatments

• Supplemental oxygen / high-flow nasal cannula (HFNC)
• Nebulized bronchodilators: albuterol/ipratropium (J7621, CPT 94640)
• CPAP / BiPAP for hypoxic respiratory failure (CPT 94660); codes J96.0x if respiratory failure documented
• Mechanical ventilation: codes J95.851 VAP if pneumonia develops after intubation; Z99.11 ventilator dependence if chronic
• Corticosteroids: dexamethasone in severe CAP/COVID pneumonia and for PCP/PJP with hypoxemia

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 8. ICD-10-CM Guidelines (FY2026)

The following guidelines govern pneumonia coding under the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting. All guidelines are effective October 1, 2025 through September 30, 2026.

Guideline 1: Organism Specificity — Code to the Highest Level of Specificity

When the organism causing pneumonia is documented or confirmed by lab results, assign the most specific organism code available (J12–J16, A48.1, B44, B59, etc.) rather than J18.9 (pneumonia, unspecified). ICD-10-CM instructs coders to code to the highest level of specificity supported by documentation. Lab results alone are insufficient — the physician/provider must document the clinical diagnosis; however, CDI query is appropriate when lab results are present but the diagnosis lacks specificity.

Guideline 2: COVID-19 Pneumonia Sequencing

Per FY2026 ICD-10-CM guidelines Section I.C.1.g, COVID-19 is coded as U07.1 as the principal/first-listed diagnosis when the patient has a confirmed COVID-19 infection. When pneumonia is present due to COVID-19, assign U07.1 first, then J12.82 (Pneumonia due to coronavirus disease 2019) as an additional code. Do NOT use J12.81 (Pneumonia due to SARS-CoV-2) for COVID-19 pneumonia — J12.81 is reserved for SARS-CoV (the 2003 epidemic strain), not SARS-CoV-2.

Guideline 3: Influenza with Pneumonia

When influenza is confirmed and complicated by pneumonia, ICD-10-CM provides combination codes. Use J09.X1 for novel/variant influenza A with pneumonia, J10.00/J10.01/J10.08 for influenza A with pneumonia (type not specified as novel), and J11.00/J11.08 for influenza B or unspecified influenza with pneumonia. These combination codes capture both the influenza and pneumonia — do not add a separate J12–J18 code unless there is a co-existing separate pneumonia of a different etiology.

Guideline 4: Aspiration Pneumonia — J69.0 Coding Instructions

Code J69.0 (Pneumonitis due to solids and liquids — aspiration pneumonia) is sequenced based on clinical circumstances:

• For aspiration of food, vomit, or oropharyngeal secretions → J69.0 is the primary pneumonia code; add a code for the underlying condition predisposing to aspiration (dysphagia R13.x, seizure R56.9, altered mental status R41.3)
• For aspiration of oils/fats → J69.1
• For chemical aspiration (gastric acid) without infection → J68.0
• For aspiration of other specific solids/liquids → J69.8
• HCC 280 capture: J69.0 maps to HCC 280 (Aspiration and Specified Bacterial Pneumonias) under CMS-HCC Model v28 with a 0.329 RAF value — significant for risk adjustment

Guideline 5: VAP — J95.851

Ventilator-associated pneumonia (J95.851) is coded as a complication of medical care. Per ICD-10-CM guidelines:

• If VAP is present on admission (POA), J95.851 may be assigned with POA = Y if the patient develops VAP as part of the reason for this admission
• Add codes for: sepsis (A40.x–A41.x) if applicable as principal diagnosis; organism using additional codes from category B95–B97
• Z99.11 (Dependence on respirator/ventilator) may be assigned additionally for long-term ventilator use

Guideline 6: Sepsis with Pneumonia

When pneumonia causes sepsis, per ICD-10-CM Section I.C.1.d, sepsis is sequenced as the principal diagnosis in most inpatient cases, with the pneumonia code as an additional code identifying the infection source. Severe sepsis (R65.20) and septic shock (R65.21) require additional codes for organ dysfunction. A41.9 (sepsis, unspecified organism) is used only when the organism cannot be specified — always query organism specificity.

Guideline 7: Fungi/Parasites — Code First Instructions

Fungal and parasitic pneumonias (J17) include mandatory “code first” instructions. The underlying condition must be sequenced first:

• B37 Candidiasis → code first, J17 additional
• B44 Aspergillosis → code first, J17 additional
• B45 Cryptococcosis → code first, J17 additional
• B58 Toxoplasmosis → code first, J17 additional
• B59 Pneumocystosis (PJP/PCP) → code first, J17 additional
• B38 Coccidioidomycosis → code first, J17 additional
• B39 Histoplasmosis → code first, J17 additional

Guideline 8: Legionella Pneumonia

Legionella pneumonia is classified to A48.1 (Legionnaire’s disease) in Chapter 1. When Legionella pneumonia is documented, assign A48.1 as principal, and add J15.8 (Pneumonia due to other specified bacteria) or J18.9 as an additional code to capture the pneumonia manifestation. Do not code A48.1 in J16 — Legionella is not Chlamydial (J16.0) and does not belong in J16.8.

🔢 9. ICD-10-CM Code Set (FY2026)

All codes below are valid for FY2026 (effective October 1, 2025 – September 30, 2026) per the CMS FY2026 ICD-10-CM Tabular List.

🔎 10. Indexing

Use the following ICD-10-CM Alphabetic Index pathways to locate pneumonia codes. Coders should verify all index entries in the FY2026 ICD-10-CM Alphabetic Index:

🏥 11. CPT (2026)

The following CPT codes are commonly reported in the evaluation, diagnosis, and treatment of pneumonia per the AMA CPT 2026 code set. All codes are subject to payer-specific coverage policies.

🧾 12. HCPCS (2026)

The following HCPCS Level II codes are relevant for pneumonia drug administration per the CMS HCPCS 2026 code set. Verify current reimbursement rates with the Medicare Part B Drug Payment schedule.

📚 13. AHA Coding Clinic (Recent Guidance)

The AHA Coding Clinic has issued several relevant advisories on pneumonia coding. Coders should review these for authoritative guidance on complex coding scenarios:

💰 14. HCC / Risk Adjustment (v28)

Under the CMS-HCC Model Version 28 (effective for calendar year 2024+ Medicare Advantage risk adjustment), pneumonia codes map as follows. Note that the majority of pneumonia codes do NOT carry direct HCC values — the key opportunities are aspiration pneumonia (HCC 280), respiratory failure complications (HCC 224/225), and sepsis (HCC 2) driven by pneumonia.

✍️ 15. CDI Query Templates

All query templates below follow ACDIS/AHIMA compliant query standards: non-leading, multiple-choice, include “clinically undetermined” as an option, and are based on clinical indicators present in the record. Do not use these queries when clinical indicators are absent.

🧑‍⚕️ 16. Treatments (Clinical)

This section provides clinical treatment context to assist CDI specialists and coders in validating the documented diagnosis against treatment received. For full treatment guidelines, refer to IDSA CAP Guidelines and IDSA HAP/VAP Guidelines.

CAP — Standard Treatment Ladder

• Outpatient (mild, no comorbidities): Amoxicillin 1g TID; if atypical suspected — doxycycline 100mg BID or azithromycin 500mg/250mg x 5d
• Outpatient (comorbidities — COPD, diabetes, renal disease): Augmentin or cephalosporin + macrolide; or respiratory fluoroquinolone (levofloxacin, moxifloxacin)
• Inpatient (non-ICU): IV ceftriaxone (J0696) + azithromycin OR IV levofloxacin monotherapy; 5–7 day course
• Inpatient (ICU/severe CAP): IV beta-lactam + macrolide; add vancomycin/linezolid if MRSA risk (post-flu, necrotizing, cavitary)

HAP/VAP — Treatment

• Empiric: Piperacillin-tazobactam (J2543) OR cefepime OR carbapenem ± vancomycin/linezolid for MRSA
• De-escalate based on culture/sensitivity results (87186)
• MDR Pseudomonas: Ceftolozane-tazobactam (J0695), ceftazidime-avibactam, or imipenem-cilastatin-relebactam
• Typical duration: 7 days; shorter courses acceptable if clinical improvement documented

Supportive Care

• Supplemental O₂ titrated to SpO₂ >92% (94% in high-risk); HFNC for moderate-severe hypoxemia
• CPAP/BiPAP (CPT 94660) for AHRF without intubation criteria; if progressive hypoxemia → intubation and invasive mechanical ventilation
• IV fluids for dehydration/sepsis resuscitation
• VTE prophylaxis in hospitalized patients
• Nutrition support — early enteral feeding in ICU patients; aspiration precautions
• Pneumococcal vaccination (PCV15, PCV20) and annual influenza vaccination at discharge

Severity Scoring (PSI/PORT and CURB-65)

Clinical severity scores guide admission decisions and CDI documentation validation:

• CURB-65 (Confusion, Urea >7, RR ≥30, BP <90/60, Age ≥65): Score 0–1 = outpatient; 2 = inpatient; 3–5 = ICU per BTS guidelines
• PSI/PORT score: Classes I–III = outpatient/low risk; IV–V = inpatient/ICU admission
• ICU-level care supports MS-DRG 177/178/179 (respiratory infection w/ MCC/CC/no CC) vs. lower-weighted DRGs

🎓 17. Patient Education / Summary

The following patient-facing summary can be adapted for discharge education, patient portals, or care coordination materials. This content reflects American Lung Association patient guidance.

What Is Pneumonia?

Pneumonia is an infection in one or both lungs. The air sacs in your lungs can fill with fluid or pus, making it hard to breathe. Pneumonia can be caused by bacteria, viruses, or fungi. It can range from mild (treated at home) to severe (requiring hospitalization and oxygen support).

Common Symptoms to Watch For

• Cough (may produce yellow, green, or blood-tinged mucus)
• Fever, chills, or sweating
• Shortness of breath, especially with activity
• Chest pain when you breathe or cough
• Fatigue and loss of appetite
• Confusion (especially in older adults)

When to Seek Emergency Care

• Difficulty breathing or very rapid breathing
• Bluish color of lips or fingertips (cyanosis)
• Chest pain that is severe or worsening
• Confusion or inability to stay awake
• Fever above 103°F (39.4°C) that does not respond to medication

Recovery and Home Care

• Take all antibiotics as prescribed — do not stop early even if feeling better
• Rest and drink plenty of fluids
• Use a cool-mist humidifier to ease breathing
• Avoid smoking and secondhand smoke
• Follow up with your doctor within 2–4 weeks; repeat chest X-ray may be needed to confirm resolution

Prevention

• Vaccinations: Pneumococcal vaccine (PCV15 or PCV20) — recommended for all adults 65+, and for younger adults with certain health conditions; annual influenza vaccine; COVID-19 vaccination; per CDC Adult Immunization Schedule
• Hand hygiene: Frequent handwashing reduces spread of respiratory pathogens
• Smoke cessation: Smoking damages lung defenses and dramatically increases pneumonia risk
• Aspiration precautions: For patients with swallowing problems — sit upright when eating/drinking; follow speech therapy recommendations

Coder/CDI Documentation Summary

For coding professionals: the most impactful documentation improvements in pneumonia encounters are (1) organism specificity — driving from J18.9 to J13–J16 or J15.211/J15.212; (2) aspiration documentation — capturing HCC 280; (3) respiratory failure type — enabling HCC 224/225; (4) sepsis documentation — enabling HCC 2 with sepsis as principal diagnosis; and (5) VAP vs. CAP identification — highest DRG weight category. These five documentation elements collectively represent the core CDI value opportunity in pneumonia and should be the focus of every pneumonia CDI review per ACDIS CDI best practices.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)